What is in the future for T-cell lymphoma?


Recently, PharmaMar announced the start of a phase 2 clinical trial to evaluate the efficacy of plitidepsin, a potential treatment option for adult patients with relapsed and refractory angioimmunoblastic T-cell lymphoma (AITL).

In this VJHemOnc – Video Journal of Hematological Oncology video, listen to Owen O’Connor, MD, PhD from Columbia University Medical Center, New York talk about the positive trend in the research for treating T-cell lymphoma.

Learn more about the study of cutaneous T-cell lymphoma genomics that is likely to lead to targeted therapies soon.

Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment